How the OneStep Partnership Could Drive Growth for ZBH Stock

Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) has entered into an exclusive collaboration with OneStep, a digital fall prevention and mobility intelligence platform, to enhance recovery tracking for joint replacement surgery patients [1][4][7] Company Developments - The collaboration will integrate OneStep's gait and mobility analytics into Zimmer Biomet's mymobility Care Management Platform, providing daily insights for patients from surgical preparation through recovery [4][5][6] - Zimmer Biomet's mymobility platform offers a guided orthopedic patient experience, including education, surveys, and video-guided post-operative exercises, supported by automation and data insights [5] - The integration of OneStep's technology supports Zimmer Biomet's connected care strategy, enhancing the ability to monitor recovery trends and tailor rehabilitation programs [6][7] Financial Performance - Zimmer Biomet has a market capitalization of $18.02 billion and an earnings yield of 8.3%, significantly higher than the industry average of 0.2% [3] - The company has delivered an average earnings surprise of 2.2% over the trailing four quarters [3] Industry Outlook - The global joint replacement market was valued at $17.1 billion in 2020 and is projected to reach $25.4 billion by 2028, growing at a compound annual growth rate (CAGR) of 3.4% from 2021 to 2028, driven by the increasing prevalence of orthopedic disorders [8] Recent Developments - Zimmer Biomet received FDA 510(k) clearance for its ROSA Knee with OptimiZe, an enhanced version of its robotic-assisted total knee replacement system, aimed at providing a more customized surgical experience [9] Stock Performance - Following the announcement of the collaboration, Zimmer Biomet's shares fell by 1.6%, but the collaboration is expected to support a rebound in stock performance [2] - Over the past year, ZBH shares have decreased by 15.9%, contrasting with the industry's growth of 0.5% [10]